希瑪眼科(03309.HK)擬配售9000萬股配售股份及發行7650萬股認購股份
格隆匯1月13日丨希瑪眼科(03309.HK)發佈公吿,2022年1月13日(交易時段前),公司、賣方(希瑪集團有限公司)、林順潮(公司一名控股股東及執行董事及保證人之一)及配售代理(UBS AG香港分行)訂立該協議,據此,配售代理同意(作為賣方的代理人)促使不少於六名買家購買合共9000萬股配售股份,或如未能成功,則配售代理同意購買配售股份,配售價為每股配售股份6.48港元;及賣方同意(作為主事人)認購及公司同意發行合共7650萬股認購股份,認購價為每股認購股份6.48港元。
配售價每股配售股份6.48港元較1月12日收市價7.18港元折讓約9.7%。配售股份總數相當於公司於該公吿日期的已發行股本約7.8%,以及相當於公司經根據認購事項配發及發行的認購股份所擴大的已發行股本約7.3%。
賣方的股權將於緊隨配售事項完成後由約60.3%減少至約52.5%。賣方所認購的新股份數量,將不會等同其在配售事項下出售的配售股份。賣方的股權將於緊隨認購事項完成後,經根據認購事項配發及發行認購股份所擴大而增加至約55.4%。公司將從認購事項獲得的所得款項總額及所得款項淨項,經扣除相關費用及開支後,估計分別約為4.957億港元及4.906億港元。公司擬將認購事項所得款項淨額用於併購的資金;擴大醫院和服務網絡;及撥充集團的一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.